CCDC171

Across TCGA pan-cancer cohorts, CCDC171 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated CCDC171 data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CCDC171 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC171 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

DLBC, HNSC, and BLCA are the cancer types where CCDC171 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
HNSC	OS	Median	All	0.156	0.710	.002	24	view →
BLCA	OS	Median	IV	0.068	0.605	<.001	18	view →
PAAD	OS	Median	All	0.132	0.613	.002	15	view →
KIRP	DFS	Median	II,III,IV	0.038	0.783	<.001	12	view →
LIHC	DFS	Median	II,III,IV	0.045	0.427	<.001	12	view →
THCA	DFS	Median	All	0.178	0.842	.010	6	view →
PRAD	DFS	Median	All	0.617	0.886	.011	6	view →
SKCM	DFS	Median	II,III,IV	0.087	0.708	<.001	6	view →
LUSC	DFS	Median	All	1.000	0.370	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

CCDC171–DLBC (OS)

Open the DLBC breakdown →